Johannes Karges is researching compounds that kill tumor cells.
Photo Credit: © RUB, Marquard
Scientific Frontline: Extended "At a Glance" Summary: Light-Activated Cuproptosis in Cancer Treatment
The Core Concept: Cuproptosis is a specific form of cell death triggered by an excess of intracellular copper. Utilizing this mechanism, researchers have developed a light-activated, copper-based agent complex embedded in polymeric nanoparticles that selectively targets and destroys cancer cells while preserving healthy tissue.
Key Distinction/Mechanism: Unlike conventional apoptosis pathways targeted by standard chemotherapy, cuproptosis is triggered when excess copper binds to mitochondrial proteins responsible for energy production, causing them to clump and inducing fatal cellular stress. To prevent damage to healthy cells, the highly toxic copper complex is encapsulated in polymeric nanoparticles that accumulate in tumors; a localized light stimulus is then used to sever a photo-responsive bond, selectively releasing the copper agent exclusively within the malignant tissue.
Major Frameworks/Components:
- Targeted Metabolic Disruption: Exploits the altered, highly active metabolism of cancer cells, which naturally intake higher levels of copper compared to healthy tissue.
- Polymeric Nanoparticle Encapsulation: A specialized carrier system that safely transports the copper agent complex, preventing premature or uncontrolled release into the bloodstream.
- Photopharmacology and Photoactivated Chemotherapy (PACT): The integration of light-sensitive (photo-responsive) bonds within the basic polymer framework, requiring specific light radiation to dissolve the nanoparticles and achieve localized, highly controlled drug delivery.
Branch of Science: Medical Inorganic Chemistry, Oncology, Nanobiotechnology, and Photopharmacology.
Future Application: This targeted methodology has the potential to become a potent clinical treatment for therapy-resistant cancers where conventional chemotherapy fails. It currently demonstrates an efficacy rate approximately 100 times greater than existing clinical platinum derivatives in laboratory settings.
Why It Matters: This advancement presents a highly precise, next-generation therapeutic strategy that simultaneously bypasses traditional chemotherapy resistance and severely limits off-target toxicity. By combining a novel cell death mechanism with controlled-release nanotechnology and light activation, it opens new avenues for treating aggressive and localized tumors.
A copper-based agent complex kills cancer cells in a novel way. It receives its activation signal through light. It could help where existing chemotherapy treatments reach their limits.
Cuproptosis was discovered in 2022. It was a previously unknown type of cell death caused by an excess of copper. The research group led by Professor Johannes Karges at Ruhr University Bochum, Germany, used this mechanism to develop a new, copper-based agent complex that kills cells 100 times more effectively than existing chemotherapy treatments. The copper complex is embedded in polymeric nanoparticles that selectively accumulate in tumor tissue. Only through activation via light do the particles dissolve and release the active ingredient, specifically killing tumor cells and preserving healthy tissue. The researchers report their findings in the journal Advanced Functional Materials.
Cancer cells take in more copper than healthy cells
Cuproptosis is fundamentally different from all previously known mechanisms of cell death: The deciding trigger is an excess of copper in the cell. It binds to certain proteins in the mitochondria that are normally responsible for energy production. These proteins clump together as a result; the cell undergoes extreme stress, and then it dies. “What makes this type of cell death so unique is its specificity in targeting the cell’s energy production,” explains Karges. “Cancer cells often have an altered, particularly intense metabolism and take in more copper than healthy tissue does.”
Karges’ team has successfully developed a copper complex that selectively induces cuproptosis. It is approximately 100 times more effective than existing platinum derivatives currently used clinically. “However, the substance was not selective at first and was fatal to healthy cells as well,” says Karges. “We were able to solve this issue by integrating the ingredient in light-activated nanoparticles.”
Packaging with dual benefits
The actual agent complex is embedded in polymeric nanoparticles. Due to the increased metabolism of cancer cells, these particles accumulate in tumors. The agent is thus selectively transported to where it is supposed to take effect. In addition, the polymer coating prevents the copper complex from being prematurely and uncontrollably released.
A light stimulus is required to release the agent on site. “The release principle is based on a photo-responsive bond within the basic polymer framework,” says Karges. “Light radiation selectively severs this specific bond, whereupon the nanoparticles dissolve and the copper complex is released locally.” This allows for highly precise and selective treatment of cancer cells. “We were also able to show that this method is effective in treatment-resistant cancer cells, where conventional chemotherapy treatments hit their limits.”
However, much research must still be done before the method can be used clinically. “So far, we have shown this on resistant cancer cells in the lab, not in a human body,” Karges emphasizes. “A lot still has to be done before an actual treatment can be performed.”
Funding: The work was supported by funds from the Verband der Chemischen Industrie e.V. as part of a Liebig grant, the Life Sciences Bridge Award from the Aventis Foundation, and the Paul Ehrlich & Ludwig Darmstaedter Early Career Award 2024 from the Paul Ehrlich Foundation.
Published in journal: Advanced Functional Materials
Authors: Ricarda Zimmermann, Nicolás Montesdeoca, and Johannes Karges
Source/Credit: Ruhr University Bochum
Reference Number: phar032626_01